Ming-Hai Wang

发表

Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2

Hui Wang, Ruiwen Zhang, Wei Wang, 2012, PloS one.

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

Ming-Hai Wang, H. Yao, X. Tong, 2020, Journal of experimental & clinical cancer research : CR.

RNA methyltransferase NSUN2 promotes gastric cancer cell proliferation by repressing p57Kip2 by an m5C-dependent manner

Ming-Hai Wang, Ji-Fu Wei, Jing-zi Wang, 2020, Cell Death & Disease.

KIAA1429 regulates cell proliferation by targeting c‐Jun messenger RNA directly in gastric cancer

Ming-Hai Wang, Ji-Fu Wei, Yun Xing, 2020, Journal of cellular physiology.

Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications

Jianwei Zhou, Hui Wang, Wei Wang, 2015, Medicinal research reviews.

Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Ruiwen Zhang, Ming-Hai Wang, Sharad K Sharma, 2013, Molecular Cancer Therapeutics.

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

Ming-Hai Wang, H. Yao, Yi Lu, 2007, Cancer letters.

Collaborative activities of macrophage-stimulating protein and transforming growth factor-β1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase

Ming-Hai Wang, Q. Shen, Yi-qing Chen, 2004, Oncogene.

Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential

Dong Wang, Ming-Hai Wang, Ming-Hai Wang, 2003, Oncogene.

Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice.

J. Buolamwini, Ruiwen Zhang, Wei Wang, 2015, Biomedical chromatography : BMC.

Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.

D. Mukhopadhyay, J. Buolamwini, Hui Wang, 2014, Gastroenterology.

Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.

Ruiwen Zhang, Jianwei Zhou, Ming-Hai Wang, 2016, American journal of cancer research.

Activation of the RON receptor tyrosine kinase protects murine macrophages from apoptotic death induced by bacterial lipopolysaccharide

Ming-Hai Wang, Yong-qing Zhou, Yi-qing Chen, 2002, Journal of leukocyte biology.

Regulation of the RON Receptor Tyrosine Kinase Expression in Macrophages: Blocking the RON Gene Transcription by Endotoxin-Induced Nitric Oxide1 2

Ming-Hai Wang, Yi-qing Chen, Hai-Lin Fung, 2000, The Journal of Immunology.

Endotoxin-Induced Nitric Oxide the RON Gene Transcription by Kinase Expression in Macrophages: Blocking Regulation of the RON Receptor Tyrosine

Ming-Hai Wang, Ming-Hai Wang, 2000 .

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Ruiwen Zhang, Jianwei Zhou, Wei Wang, 2015, Methods in molecular biology.

Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.

Ruiwen Zhang, Ming-Hai Wang, Sunny Guin, 2011, Molecular pharmaceutics.

Prevention of BMS‐777607‐induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Ruiwen Zhang, Jianwei Zhou, Ming-Hai Wang, 2014, Molecular oncology.

MSP–RON signalling in cancer: pathogenesis and therapeutic potential

Ruiwen Zhang, Ming-Hai Wang, Ruiwen Zhang, 2013, Nature Reviews Cancer.

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

Tianhao Weng, Zhigang Wu, Ming-Hai Wang, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Tianhao Weng, Zhigang Wu, Ming-Hai Wang, 2019, Front. Oncol..

Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy

Ming-Hai Wang, Sunny Guin, Yong-qing Zhou, 2010, Acta Pharmacologica Sinica.

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Ming-Hai Wang, H. Yao, X. Tong, 2021, Therapeutic advances in medical oncology.

Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction

Ruiwen Zhang, Ming-Hai Wang, H. Yao, 2013, Journal of biomedical research.

Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers

Ming-Hai Wang, H. Yao, Yong-qing Zhou, 2006, Acta Pharmacologica Sinica.

Modulation of lipopolysaccharide-induced production of tumor necrosis factor, interleukin 1, and interleukin 6 by synthetic precursor Ia of lipid A.

J. Gerdes, H. Flad, Ming-Hai Wang, 1992, FEMS microbiology immunology.

The optimum marker for the detection of lymphatic vessels

Ming-Hai Wang, Wenbin Zhou, Q. Ding, 2017, Molecular and clinical oncology.

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Ruiwen Zhang, Jianwei Zhou, Ming-Hai Wang, 2016, Journal of Experimental & Clinical Cancer Research.

Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Ruiwen Zhang, Jianwei Zhou, Ming-Hai Wang, 2016, Journal of Experimental & Clinical Cancer Research.

Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure–Activity Relationships, and Molecular Mechanisms of Action

Hui Wang, Ruiwen Zhang, Wei Wang, 2012, Front. Pharmacol..

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

K. Srivenugopal, J. Buolamwini, Hui Wang, 2014, Nature Communications.

Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop

Hui Wang, Ruiwen Zhang, H. Wang, 2013, Oncogene.

The pathological significance of abnormal RON and PD-L1 expression in colorectal cancer

Zhigang Wu, Danrong Shi, Ming-Hai Wang, 2020 .

Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Ruiwen Zhang, Jianwei Zhou, Wei Wang, 2014, Clinical Cancer Research.

RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells

Ming-Hai Wang, Q. Shen, Yi-qing Chen, 2004, Oncogene.

Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.

Ruiwen Zhang, Ming-Hai Wang, H. Yao, 2013, Current cancer drug targets.

Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein

Ruiwen Zhang, Ming-Hai Wang, Sunny Guin, 2011, Molecular Cancer.